The Lundquist Institute will have a float in the 2022 Rose Parade called “Impositive” to celebrate its 70th Anniversary.
The Lundquist Institute will have a float in the 2022 Rose Parade called “Impositive” to celebrate its 70th Anniversary. The float is sponsored by Impositivity Media and Emmaus Life Sciences and will feature riders whose lives have been saved by groundbreaking research conducted at the Institute. The Lundquist Investigators responsible for the life-saving therapies, Dr. Emil Kakkis and Dr. Yutaka Niihara, will also be riding on the float along with their former patients and Institute PhD students.
Eli Ipp, MD, is Lead Author on a JAMA Open Network Study that Positively Evaluates EyeArt AI System to Prevent Diabetic Vision Loss
The study examines performance of the EyeArt AI system for detecting eyes with more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR).
The Lundquist Institute’s Investigator Eli Ipp, MD, and a multi-center team of investigators have evaluated the performance of the EyeArt AI system in a study published in JAMA Open Network. Dr. Ipp and his co-investigators found that the accuracy of the EyeArt AI system was high in detecting mtmDR (sensitivity 96% and specificity 88%) and vtDR (sensitivity 97% and specificity 90%).
Institute Investigators Develop a Significant Novel Mouse Model of the Neuropediatric Disorder Ataxia Telangiectasia (A-T)
Ataxia Telangiectasia (A-T) Is a Devastating Disorder in Children Characterized by a Severe Loss of Motor Coordination (Ataxia), Increased Cancer Susceptibility, Immunodeficiency, and Premature Death
The Lundquist Institute’s investigators have developed a critically needed mouse model of Ataxia Telangiectasia (A-T), a currently untreatable, rare childhood disorder that results in a severe and progressive loss of motor coordination and premature death by 30 years of age. The disorder is caused by recessive genetic mutations in the A-T mutated (ATM) gene that prevent the production of an important DNA repair pathway protein referred to as ATM.
The Lundquist Institute’s Male Contraceptive Efficacy Trial has received an additional $3 million from the National Institutes of Health (NIH) to expand its work and recruit 120+ more couples.
The Lundquist Institute’s Male Contraceptive Efficacy Trial has received an additional $3 million from the National Institutes of Health (NIH) to expand its work and recruit 120+ more couples. This NIH funding will bring the total number of couples involved in the study to over 400.
The CIRM Grant Will Support Stem Cell Training and Research for the Institute’s PhD Students, Postdoctoral Fellows and Clinical Fellows
LOS ANGELES (September 24, 2021) — The Lundquist Institute (TLI) announced that it has received a generous $5 million, 5-year grant from the California Institute for Regenerative Medicine (CIRM) that will allow its PhD students, postdoctoral fellows and clinical fellows to pursue careers in stem cell biology and regenerative medicine.
Lundquist Institute Investigators Find That Early Administration of Convalescent Plasma Does Not Prevent COVID-19 Disease Progression
Convalescent plasma from blood donors who have recovered from COVID-19 does not prevent disease in acutely ill, high-risk patients with COVID-19.
LOS ANGELES — The Lundquist Institute announced that, in a new study published today in The New England Journal of Medicine, its Investigators and research colleagues at other institutions have found that passive immunization by infusion of COVID-19 convalescent plasma is not a viable strategy to reduce the severity of illness. Plasma from recovered patients who have already developed antibodies to SARS-CoV-2 is often the most readily available source of antibodies early in epidemics or emerging infections.
LOS ANGELES — BioLabs LA at The Lundquist Institute, a co-working and incubator facility for high-potential bioscience start-ups, has reached 100% capacity ahead of schedule. This critical milestone demonstrates the strong demand for entrepreneurial startup opportunities in the bioscience sphere in Los Angeles.
Lundquist Institute Investigators Contribute to Global Study Expanding Genomic Research Into Different Ancestries
Paper in Nature Genetics: Genome-wide Meta-Analysis Shows That Research into Different Ancestries Leads to Better Results and Better Care
LOS ANGELES — Today The Lundquist Institute announced that its investigators contributed data from several studies, including data on Hispanics, African-Americans and East Asians, to the international MAGIC collaboration, composed of more than 400 global academics, who conducted a genome-wide association meta-analysis led by the University of Exeter. Now published in Nature Genetics, their findings demonstrate that expanding research into different ancestries yields more and better results, as well as ultimately benefitting global patient care.
Lundquist Institute Investigator Wei Yan, MD, PhD, Solves Longstanding Fallopian Tube Transport Debate
Yan Group’s Research Shows That Motile Cilia Are Key to Oocyte Pickup in the Fallopian Tube
Unlike the normal Fallopian tube (left), the "cilia-less" Fallopian tube fails to pick up ovulated eggs, leading to female infertility (right). Art by Tingting Xie.
LOS ANGELES — Today, The Lundquist Institute announced that Wei Yan, MD, PhD, and his research group have solved a longstanding mystery and scientific debate about the mechanism underlying the gamete and embryo transport within the Fallopian tube. Using a mouse model where the animals lacked motile cilia in the oviduct, Dr.
Lundquist Institute Investigator Ashraf Ibrahim, PhD, Leads Life-Saving Research on Mucormycosis, the Deadly “Black Fungus”
Dr. Ibrahim’s start-up Vitalex Biosciences is manufacturing humanized monoclonal antibodies that would stem the spread of this fatal disease
LOS ANGELES — The Lundquist Institute today announced that one of its spinoff start-up companies, Vitalex Biosciences, founded by researcher Dr. Ashraf Ibrahim, is producing an antibody that stems the spread of mucormycosis, a deadly fungal infection with an overall mortality rate of 50% and higher. Mucormycosis is an emerging infection caused by exposure to mucor, a mold commonly found in soil, plants, manure, and decaying fruits and vegetables.